PHILADELPHIA courtrooms will
next year see lawyers for Bayer
and Janssen, the sponsors of NOAC
Xarelto (rivaroxaban), defending
more than 800 lawsuits around
claims of injury resulting from
trials conducted prior to the drug’s
approval by the FDA, according to a
report by Forbes.
Plaintiffs claim they experienced a
risk of bleeding events when taking
the drug once per day rather than
twice per day, an matter of which
they say they were inadequately
warned.
One Philadelphia medical
malpractice attorney who
represents Xarelto users called one
of the drug trials “a total mess” and
“compared it to a school science
fair project,” the report said.The above article was sent to subscribers in Pharmacy Daily's issue from 01 Jul 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Jul 16
THE role and significance of community pharmacy in regional areas was a key focus of discussion for the Nationals leader David Littleproud during last week’s visit to Orana Mall Pharmacy as part of a regional tour.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.